about
Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patientsABCB1 1199G>A genetic polymorphism (Rs2229109) influences the intracellular accumulation of tacrolimus in HEK293 and K562 recombinant cell linesInteraction between Darunavir and Etravirine Is Partly Mediated by CYP3A5 PolymorphismCYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity.The Val158Met polymorphism of the COMT gene is associated with increased pain sensitivity in morphine-treated patients undergoing a painful procedure after cardiac surgery.The CYP3A4*22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrationsImpact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinibClinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks.Pharmacogenetics in kidney transplantation: recent updates and potential clinical applications.The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach.Genetic Predisposition to Poor Opioid Response in Preterm Infants: Impact of KCNJ6 and COMT Polymorphisms on Pain Relief After Endotracheal Intubation.Dental Apical Papilla as Therapy for Spinal Cord Injury.Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation.Single-nucleotide polymorphisms in P450 oxidoreductase and peroxisome proliferator-activated receptor-α are associated with the development of new-onset diabetes after transplantation in kidney transplant recipients treated with tacrolimus.Functional defect caused by the 4544G>A SNP in ABCC2: potential impact for drug cellular disposition.CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation.Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients.Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients.Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines.Advanced cancer pain: the search for genetic factors correlated with interindividual variability in opioid requirement.No effect of CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) on lipid-lowering response to statins in Greek patients with primary hypercholesterolemia.Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin.Acute intoxication with nevirapine in an HIV-1-infected patient: clinical and pharmacokinetic follow up.Validation and clinical application of a high performance liquid chromatography tandem mass spectrometry (LC-MS/MS) method for the quantitative determination of 10 anti-retrovirals in human peripheral blood mononuclear cells.Quantification of 8 HIV-protease inhibitors and 2 nonnucleoside reverse transcriptase inhibitors by ultra-performance liquid chromatography with diode array detection.Effect of UGT2B7 -900G>A (-842G>A; rs7438135) on morphine glucuronidation in preterm newborns: results from a pilot cohort.The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients.Genetic variation in the PPARA gene is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study.ABCB1 1199G>A polymorphism (rs2229109) affects the transport of imatinib, nilotinib and dasatinib.A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.POR*28 SNP is associated with lipid response to atorvastatin in children and adolescents with familial hypercholesterolemia.Detection of a rare CYP3A4 variant in a transplant patient characterized by a tacrolimus poor metabolizer phenotype.Impact of UGT1A1 polymorphisms on Raltegravir and its glucuronide plasma concentrations in a cohort of HIV-1 infected patients.Effect of ABCB1 genetic polymorphisms on the transport of rivaroxaban in HEK293 recombinant cell lines.Effect of a new functionalCYP3A4polymorphism on calcineurin inhibitors’ dose requirements and trough blood levels in stable renal transplant patientsCYP3A5 and ABCB1 Polymorphisms and Tacrolimus Pharmacokinetics in Renal Transplant Candidates: Guidelines from an Experimental StudySLC22A1/OCT1 Genotype Affects O-desmethyltramadol Exposure in Newborn InfantsAssociation of CYP3A variants with kidney transplant outcomesRivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study
P50
Q28293875-7E71ABDB-C249-4C3D-B129-7263BB0C0D63Q28540793-71CFFBBE-1078-478E-BA5A-DE1806A819A7Q28552997-00F787D6-149B-4E50-BFE6-E856BD1897ABQ36940993-64CC380D-D12F-49C7-AB29-67FBAF7738EDQ36948127-84C4D54A-534C-4659-8025-8DCA2F91D399Q36948144-B7122B26-71FE-488B-A991-1BF05A5EB355Q37087238-BA379C76-9065-4341-8691-E97EA5147D3BQ37678060-F8165A51-AFA3-4866-8CAC-E7530C17C383Q38063426-CE40600E-4294-4C62-B08A-0083FC8FD7DCQ38163945-29510FFD-AA35-4458-B3F1-28E458508FEEQ39041618-8FE25EC8-2A9B-458F-B0EE-A6E9D26DC0F8Q39174714-20D5337D-5DC3-497C-B66F-C26D45EE13FEQ40571237-A84A659F-86F6-41B6-A5F3-6E1B0867EDCAQ42215557-9C2FACE6-727A-4075-A500-38661B8B51CDQ42708972-2E803CAB-FFA5-4ED5-BF91-AE7A7130ABA3Q42725704-4CE7CE62-9D54-40F3-A99F-D4AC5CB18446Q43087572-979F7C12-D01A-4522-862F-A84B18919ABFQ43258274-2A12FD9B-E2CF-46CC-9FD8-A811A78750E8Q43597474-6B6FFBC0-D496-4FF9-9575-CCE496BB287FQ43977791-A1B0844F-8B85-4191-89EB-A8BE6CD16321Q44347588-689A3D8C-48EC-4C0E-A6B3-B99B750DB02EQ45010918-BCE1AF7A-F044-4C4F-A337-FE885F33C48EQ45786974-187E9CA8-4570-44DC-AB6A-F7C8D2BE1DCDQ45976024-F2FB1925-31FF-44C4-9011-955836AE17D7Q45987306-3FECBCDB-3D5E-4ACD-AD4E-4732E48453CEQ46231537-306CD839-A83F-4A9D-846D-5679B15DFC3CQ47796637-0CABD20E-A5A0-4651-ABFB-1CC732EBD53BQ47803890-A71B276E-E895-4CA4-A755-DB0FBB082DB5Q47820302-E31FFC09-3D01-45E2-9DE1-443D0B0A35C7Q51717149-1F48F578-6A54-43C8-B229-9F5450ABE8CFQ53146395-1B295844-53EE-419D-9734-C2A3075DF64DQ53665083-1B887D78-D81C-4999-B586-261F253A2CD8Q53827932-631395DA-4B77-488E-85C2-27C3A625BACCQ54216681-A6868A42-150D-4E31-BB7F-D37329F89551Q55662488-76F57F1C-951B-4E16-A265-6F8CDD252CFAQ56834587-C1164D69-8FFF-43F7-85A0-FFBB55EB8E4DQ56834660-5C28DA72-B35F-4ED1-AFD7-87F4B1CDB1C1Q56924245-59E175A8-34D2-44F3-AF06-B3BAD8433D05Q57845197-9D2FB449-A028-43AD-A2CA-512EB35A0B27Q59129911-3EBF7F88-68C4-4A34-B2C3-F6F58A89CB11
P50
description
researcher ORCID ID = 0000-0002-0039-3583
@en
name
Laure Elens
@ast
Laure Elens
@en
Laure Elens
@es
Laure Elens
@nl
type
label
Laure Elens
@ast
Laure Elens
@en
Laure Elens
@es
Laure Elens
@nl
prefLabel
Laure Elens
@ast
Laure Elens
@en
Laure Elens
@es
Laure Elens
@nl
P108
P1153
21933445000
P21
P31
P496
0000-0002-0039-3583